Trial Profile

Biomarker Analysis of Neoadjuvant Intralesional Therapy in High Risk Early Melanoma

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 20 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talimogene laherparepvec (Primary) ; Talimogene laherparepvec (Primary)
Indications Malignant melanoma
Focus Biomarker; Therapeutic Use

Most Recent Events

13 Sep 2023 Status changed from recruiting to suspended.
16 Jun 2022 Planned primary completion date changed from 21 May 2022 to 21 Dec 2022.
15 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com